We are pleased to introduce our new product: a B2B platform named PhL1 PLAZA that creates value by facilitating exchanges between Licensor and Licensee.
PhL1 PLAZA targets capabilities that help you accomplish hard-to-reach projects.
PhL1 PLAZA is a B2B platform both for Licensors and Licensees/Distributors to reach potential partners who are already interested in what you have to offer. We offer only those projects that passed our internal rigorous audit.
PhL1 PLAZA targets capabilities that help you accomplish hard-to-reach projects.
PhL1 PLAZA is a B2B platform both for Licensors and Licensees/Distributors to reach potential partners who are already interested in what you have to offer. We offer only those projects that passed our internal rigorous audit.
Expanding the product portfolio by licensing or acquiring new products or technologies, which can help diversify current markets and reach new ones.
Accessing innovative technologies by acquiring licenses to innovative technologies, and stay competitive and keep up with the latest advancements in the industry.
Accessing innovative technologies by acquiring licenses to innovative technologies, and stay competitive and keep up with the latest advancements in the industry.
We make public non-confidential info about opportunities both Licensee and Licensor offer. Should you be interested in the project below, please send your request at business@pharmalicensingone.com
or WhatsApp +35795726275.
or WhatsApp +35795726275.
Licensing – IN
In-licensing include rights to develop, manufacture, and market a particular product and expand Licensee’s product portfolio without having to develop the product or technology in-house.
Licensing – OUT
The product developer (licensor) allowing another company (the licensee) to use its intellectual property, such as patents or know-how, in exchange for license fee, royalties, or other agreed-upon terms.
Co-Development Licensing
Collaboration between a licensor and licensee in jointly developing a pharmaceutical product which is suitable when both parties possess complementary expertise and resources that can enhance the chances of success. The licensor and licensee share costs and risks and responsibilities associated with R&D, manufacturing and regulatory.
M&A and Asset Acquisition
Mergers and acquisitions in pharmaceutical/biotech and medical device industry are strategic maneuvers that reshape the industry landscape to foster innovation, expand research capabilities and increase market competitiveness.
Synergy capture is one of the most effective ways to create value in pharmaceutical and biotech M&A by means of identifying and capturing the value of combining two or more companies. This can include fast RoI with revenue growth, cost savingsand access to new markets and product categories.
In-licensing include rights to develop, manufacture, and market a particular product and expand Licensee’s product portfolio without having to develop the product or technology in-house.
Licensing – OUT
The product developer (licensor) allowing another company (the licensee) to use its intellectual property, such as patents or know-how, in exchange for license fee, royalties, or other agreed-upon terms.
Co-Development Licensing
Collaboration between a licensor and licensee in jointly developing a pharmaceutical product which is suitable when both parties possess complementary expertise and resources that can enhance the chances of success. The licensor and licensee share costs and risks and responsibilities associated with R&D, manufacturing and regulatory.
M&A and Asset Acquisition
Mergers and acquisitions in pharmaceutical/biotech and medical device industry are strategic maneuvers that reshape the industry landscape to foster innovation, expand research capabilities and increase market competitiveness.
Synergy capture is one of the most effective ways to create value in pharmaceutical and biotech M&A by means of identifying and capturing the value of combining two or more companies. This can include fast RoI with revenue growth, cost savingsand access to new markets and product categories.
Our client is an Asian R&D company offers Afliberceptphase 2 clinical studies for licensingwith TT at a Licensee’s CMO.
Aflibercept global sales valued US$13 billion in 2023 according IQVIA.
An Asian developing company completed the 2nd phase of clinical studies with developing a technology for a capacity of 500L scale-up manufacturing process.
The Licensee responsibilities in outline:
Project highlights, below:
Aflibercept global sales valued US$13 billion in 2023 according IQVIA.
An Asian developing company completed the 2nd phase of clinical studies with developing a technology for a capacity of 500L scale-up manufacturing process.
The Licensee responsibilities in outline:
- To complete a phase 3 clinical trial meeting local regulatory requirements.
- Transfer Licensor’s technology at in-house or CMO.
Project highlights, below:
Ref.: Aflibercept Co-Development Licensing to ex-USSR and RoW / Sep 2024
Parameter
Product
Indication
Manufacturing site
Deal parameter
Important info
Aflibercept
Are the same as those of the originator Eylea®
TT at the Licensee’s CMO
Co-Development Licensing
Description
Aflibercept patent search for a local market novelty is exercised by a Licensee
The Licnesee has to complete a phase 3 clinical trial according to the local requirements along with license a technology at own CMO
Territory: ex-USSR and RoW
The Licnesee has to complete a phase 3 clinical trial according to the local requirements along with license a technology at own CMO
Territory: ex-USSR and RoW
The global Alzheimer's therapeutics market size is estimated to grow from USD 4.82 billion in 2023 to surpass around USD 8.18 billion by 2032, registering a CAGR of 8.7% between 2024 and 2032. Cholinesterase inhibitors lead the market with a commanding 50% market share in 2023.
Our client is an Asian R&D company is currently developing a potential super blockbuster candidate medicine for Early-stage Alzheimer’s disease (AD) which is currently in global clinical phase 3, aiming for 1150 patients in 11 countries of the EU (7 member states), the US, UK, China, and South Korea at the same time. So, an Asian developer looks for Licensees to the ex-USSR and RoW.
The Licensee’s responsibilities in the Territory in outline:
Project highlights, below:
Our client is an Asian R&D company is currently developing a potential super blockbuster candidate medicine for Early-stage Alzheimer’s disease (AD) which is currently in global clinical phase 3, aiming for 1150 patients in 11 countries of the EU (7 member states), the US, UK, China, and South Korea at the same time. So, an Asian developer looks for Licensees to the ex-USSR and RoW.
The Licensee’s responsibilities in the Territory in outline:
- To file Licensor’s phase 3 clinical trial as per local regulatory guideline.
- Transfer Licensor’s technology at in-house or CMO.
Project highlights, below:
Ref.: A Potential Super Blockbuster Candidate for Early-Stage Alzheimer Disease for Co-Development Licensing to the Ex-USSR and RoW / Oct 2024
Parameter
Product
Indication
Manufacturing site
Deal parameter
Important info
Early-stage AD molecuel
Basically, are the same as those of cholinesterase inhibitors
TT at the Licensee’s CMO
Co-Development Licensing
Description
To file Licensor’s phase 3 clinical trial as per local regulatory guideline or arrange local phase 3 studies if needed
Transfer Licensor’s technology at in-house or CMO
Territory: ex-USSR and RoW
Transfer Licensor’s technology at in-house or CMO
Territory: ex-USSR and RoW
The global testosterone replacement therapy market size was valued at $1.9 billion in 2022, and is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
Our client is a well established R&D and manufacturing company (6 production sites in EU)is currently searching for licensing-IN or co-development licensing a testosterone gel to its key markets.
Project highlights, below:
Our client is a well established R&D and manufacturing company (6 production sites in EU)is currently searching for licensing-IN or co-development licensing a testosterone gel to its key markets.
Project highlights, below:
Ref.: Scouting a Licensing Testosterone Gel to EU and former USSR / Oct 2024
Parameter
Product
Parameter
Manufacturing site
Product
Indication
Deal parameter
Indication
Manufacturing site
Target markets
Deal parameter
Target markets
Testosterone gel 50 mg / 5 g
Basically, are the same as those of Besin’s Androgel®
TT at the Licensee’s CMO
Russia/EAEU and Former USSR
Indolecarbinol 200 mg, 60 caps
Shelf-life: 2 years
Shelf-life: 2 years
Description
Description
Russian CMO or
TT at the Licensee’s CMO
TT at the Licensee’s CMO
EU (5+ member states)
Former USSR
Former USSR
Treatment of cyclic mastalgia (mastodynia), including against the background of benign hyperplasia of the mammary gland
Co-development Registration Dossier (including BE studies) for further filing by a Licensee
Licensing dossier and supply agreement of FDF or
Licensing dossier and TT at a Licensee’s site in EU or
Co-Development Licensing
Licensing dossier and TT at a Licensee’s site in EU or
Co-Development Licensing
Ref.: Licensing-In with
Co-Development of Indolecarbinol used in treatment of cyclic mastalgiato ex-USSR / Oct 2024
Co-Development of Indolecarbinol used in treatment of cyclic mastalgiato ex-USSR / Oct 2024
Licensing - IN
Co-Development Licensing
Co-Development Licensing
Co-Development Licensing
PHL1 PLAZA
The essence of PHL1 PLAZA proposal
Advantages for our clients
How that works
- $16.326.531 (17%)
- 500.000 packs (14%)
- $13.550.405 (20%)
- 429.162 packs (16%)
- $10.855.962 (18%)
- 360.367 (18%)
- $8.927.819
- 296.920
- MAT/2025/MTH08 (F)
- MAT/2024/MTH08
- MAT/2023/MTH08
- MAT/2022/MTH08
The Indolecarbinol Russian pharmaceutical market is represented by one brand manufactured locally.
Indolecarbinol 200 mg, 60 caps, Russian market insights (sales value (USD) / sales volume (packs/FDF) with growth (%):
Indolecarbinol 200 mg, 60 caps, Russian market insights (sales value (USD) / sales volume (packs/FDF) with growth (%):
Source: IQVIA Russia
Our client is a Russian R&D has been developed a patented technology of Indolecarbinol API synthesis with in-house manufacturing site for scale up API manufacturing.
Project highlights, below:
Our client is a Russian R&D has been developed a patented technology of Indolecarbinol API synthesis with in-house manufacturing site for scale up API manufacturing.
Project highlights, below:
Our client is a Russian public R&D and manufacturing company offers a development of a syrup with modified composition differ from 2 competitors in the Russian market.
Turn-key project includes:
Project highlights, below:
Turn-key project includes:
- Development of a dossier
- Obtaining MA under the EAEU procedure on the Licensee’s name
- FDF manufacturing at Licensor’s in-house manufacturing site
Project highlights, below:
Ref.: Rimantadine Syrup Turn-Key Development for EAEU / Sep 2024
Parameter
Product
Indication
Manufacturing site
Deal parameter
Important info
Syrup (for children) 2 mg / 1 ml: 100 ml bottle
Active ingredient: Rimantadine registered by WHO
Prescribing: Rx
Shelf-life: 3 years
Active ingredient: Rimantadine registered by WHO
Prescribing: Rx
Shelf-life: 3 years
Prevention and treatment of influenza and acute respiratory viral infections in children from 1 to 7 years old
In-house EAEU GMP-certified site
Dossier licensing with MA and FDF supply
Description
Patentability of the development
Rimantadine Russian market (all forms), 2023: xxx Roubles (equal to xx mln EUR), xxx packs
Liquid forms MS: % from value and % from volume, and liquid forms show stable growth
The project from development to licensing MA will take 3.5 year
Rimantadine Russian market (all forms), 2023: xxx Roubles (equal to xx mln EUR), xxx packs
Liquid forms MS: % from value and % from volume, and liquid forms show stable growth
The project from development to licensing MA will take 3.5 year
Our client is a Russian public R&D and manufacturing company offers a development of a syrup for for potential Licensee. Turn-key project includes:
Project highlights, below:
- Development of a dossier
- Obtaining MA under the EAEU procedure on the Licensee’s name
- FDF manufacturing at Licensor’s in-house manufacturing site
Project highlights, below:
Ref.: Ibuprofen Syrup Development for EAEU / Sep 2024
Parameter
Product
Indication
Manufacturing site
Deal parameter
Important info
Syrup (for children) 100 mg / 5 ml: 100 ml bottle
Active ingredient: Ibuprofen registered by WHO
Prescribing: OTC
Shelf-life: 3 years
Active ingredient: Ibuprofen registered by WHO
Prescribing: OTC
Shelf-life: 3 years
Symptomatic treatment as an anti-inflammatory and antipyretic agent: inflammatory and degenerative diseases of the joints and spine etc.
In-house EAEU GMP-certified site
Dossier licensing with MA and FDF supply
Description
The project from development to licensing MA will take 3+ year
Our client is a Russian LLC with Asian shareholders decided to sell their Russian asset due to change of a corporate strategy in this part of the world.
Project highlights, below:
Project highlights, below:
Ref.: Russian Pharmaceutical Manufacturing Site Acquisition Offer / Aug 2024
Parameter
Asset
Territory
Deal parameter
Manufacturing site
Important info
Solid Presentations Pharmaceutical Factory in Russia
Central Russia Area, 500 km from Moscow
100% share for sale
Land lot – 3,000 m2,
building – 1,500 m2,
manufacturing area – 1,200 m2,
clean area – 300 m2
Clean area, water engineering, steam generator, power heating 24 kWt, power – 250 kWt + distribution 250 kWt etc
building – 1,500 m2,
manufacturing area – 1,200 m2,
clean area – 300 m2
Clean area, water engineering, steam generator, power heating 24 kWt, power – 250 kWt + distribution 250 kWt etc
Description
There was no finished product production, no pharmaceutical license of Minpromtorg Russia a local regulator
Our Client is a traditional French company with 100-year + history, a developer and manufacturer of high-quality medical devices, healthcare products and medical cosmetics looks for distributors in a former USSR.
Project highlights, below:
Project highlights, below:
Ref.: French Healthcare Products for Distribution in ex-USSR
/ Sep 2024
/ Sep 2024
Parameter
Product
Territory
Manufacturing site
Deal parameter
MA and TM
Baby's Health and Infant Nutrition
Respiratory, ENT and Ophthalmology
Natural Health
Family Pharmacy incl. anti lice and anti-mosquito
Respiratory, ENT and Ophthalmology
Natural Health
Family Pharmacy incl. anti lice and anti-mosquito
Former ex-USSR member states
In-house manufacturing site in France
Distribution
Description
MA and TM remain with a French company
Co-Development Licensing
Co-Development Licensing
Licensing - OUT
Licensing - OUT
M&A and Asset Acquisition
©2024 Pharmalicensing One, LLC 9/3/2024
Our client is EU-based R&D pharmaceutical company a MAH of Phloroglucinol ODT, offers licensing to global markets. The company follows superior business ethical standards all across its business process – from development to production.
Project highlights, below:
Project highlights, below:
Ref.: Phloroglucinol ODT Licensing to EU, MENA and ex-USSR / May 2024
Parameter
Product
Territory
Deal parameter
Manufacturing site
Important info
Phloroglucinol 80 mg ODT
Indicated in the treatment of pain caused by spasms (cramps) in the intestines, biliary tract, bladder and uterus as specified in the PIL
EU CTD
Reference product: SPASFON -SANOFI
Stability zone ii and iv
Indicated in the treatment of pain caused by spasms (cramps) in the intestines, biliary tract, bladder and uterus as specified in the PIL
EU CTD
Reference product: SPASFON -SANOFI
Stability zone ii and iv
EU except GR, CY, RO, BL, IT
MENA
APAC
Former USSR
MENA
APAC
Former USSR
Licensing dossier + FDF supply
Licensee’s private label
Licensee’s private label
An Asian vertically integrated EU GMP-certified factory produces both API and FDF
Description
Safety profile (prescribes in pediatrics) vs. buscopan a major competitor
A free pricing drug with OTC status in a few EU markets incl. France with annual market worth 55 mln EUR +
A free pricing drug with OTC status in a few EU markets incl. France with annual market worth 55 mln EUR +
Our Client is a Korean R&D and manufacture of a biomaterial for tissue restoraration using Polynucleotide (PN) which can be used in KOA and mesotherapy, looks for exclusive distributors in EU, and former USSR.
Project highlights, below:
Project highlights, below:
Ref.: Portfolio of Knee Oeteoarthritis (KOA) and Mesotherapy for distribution in EU and ex-USSR / Apr 2024
Parameter
Product
Territory
Deal parameter
Manufacturing site
MA and TM
High molecular DNA polymer with Viscoelasticity in prefilled syringes for KOA and Mesotherapy
Medical device Class III
CE mark and ISO
Medical device Class III
CE mark and ISO
EU and ex-USSR
Exclusive distribution
In-house manufacturing site in S.Korea
Description
MA - the Distributor will run the MA procedure and medical device vigilance at own expense then
TM remains with a Korean MAH
TM remains with a Korean MAH
Our Client is an EU-based R&D medical company has been developed a unique anti-inflammatory medical device for wound care – treatment of chronic inflammation and edema.
Project highlights, below:
Project highlights, below:
Ref.: PEMF Technology Medical Device for Wound Care – Licensing to RoW ex-USSR / Aug 2024
Parameter
Product
Territory
Deal parameter
Manufacturing site
Important info
A wearable patch that uses Pulsed Electro Magnetic Field (PEMF) technology to reduce exudate/edema/inflammation
It is medical device Class I
It is medical device Class I
RoW and ex-USSR
Exclusive distribution or licensing
The Licensee/Distributor will run registration in the Territory and be the MAH and will run the medical device vigilance then
Private label is possible
The Licensee/Distributor will run registration in the Territory and be the MAH and will run the medical device vigilance then
Private label is possible
In-house manufacturing site in EU
Description
Various clinical and case reports available
No patent
It is NOT a T.E.N.S.
It is NOT magnetotherapy since it works through a not continuous pulsed electromagnetic field
It is NOT sterile
No patent
It is NOT a T.E.N.S.
It is NOT magnetotherapy since it works through a not continuous pulsed electromagnetic field
It is NOT sterile
Our client is an international pharmaceutical company with in-house R&D and manufacturing sites in EU and Asia, has been developed Ketorolac SL tabs with better and quicker absorption than IM or oral tablet for the short treatment of severe pain in adults.
Market Highlights and Competitors’ Landscape
The global Analgesics market is valued at $21.2 billion in 2020 is expected to reach $23.0 billion by the end of 2026 (CAGR 1.1%). Oral analgesics for acute pain include Paracetamol, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. For moderate to severe pain tramadol, propoxyphene and codeine are widely used.
Project highlights, below:
Market Highlights and Competitors’ Landscape
The global Analgesics market is valued at $21.2 billion in 2020 is expected to reach $23.0 billion by the end of 2026 (CAGR 1.1%). Oral analgesics for acute pain include Paracetamol, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. For moderate to severe pain tramadol, propoxyphene and codeine are widely used.
Project highlights, below:
Ref.: Ketorolac Sublingual (SL) tabs for licensing to the RoW and ex-USSR / Dec 2023
Parameter
Product
Territory
Deal parameter
Manufacturing site
Important info
Ketorolac tromethamine
Dosage form - 10 mg sublingual tab
Zone II andIVb Stability data
eCTD dossier - ANVISA, Brazil format
Pack info - Amber colored PVC/PVDC Aluminum blister
Dosage form - 10 mg sublingual tab
Zone II andIVb Stability data
eCTD dossier - ANVISA, Brazil format
Pack info - Amber colored PVC/PVDC Aluminum blister
RoW and ex-USSR
In-licensing + supply FDF or blister
Licensee runs local BE studies and obtaining MA in the Trerritory
Licensee is a MAH with its private label in the Territory
Licensee runs local BE studies and obtaining MA in the Trerritory
Licensee is a MAH with its private label in the Territory
In-house manufacturing site in Asia
EU-, EAEU-, WHO-,THA-, UAE MoH- SAHPRA-, Safety Korea-, Health Canada-ANVISA-GMP certified manufacturing site
EU-, EAEU-, WHO-,THA-, UAE MoH- SAHPRA-, Safety Korea-, Health Canada-ANVISA-GMP certified manufacturing site
Description
SL formulation allows a rapid and direct absorption of the active ingredient bypassing hepatic first- pass metabolic processes seen with conventional oral route formulations.
Ketorolac is highly effective for prostaglandin-mediated pathologies causing pain and inflammation including trauma.
Ketorolac SL has been shown to be as effective as metamizole in the management of pain in short-stay surgeries.
Ketorolac SL is also as effective as piroxicam sublingual in the management of postoperative pain, trismus and swelling management in lower third molar removal.
Ketorolac is highly effective for prostaglandin-mediated pathologies causing pain and inflammation including trauma.
Ketorolac SL has been shown to be as effective as metamizole in the management of pain in short-stay surgeries.
Ketorolac SL is also as effective as piroxicam sublingual in the management of postoperative pain, trismus and swelling management in lower third molar removal.
Licensing - IN
Licensing - OUT
Licensing - OUT
Licensing - OUT
Our client is a group of companies with pharmaceutical distribution, pharmacy chain, and a pharmaceutical factory assets. They look for in-licensing a vitamin D3 injectable.
Project highlights, below:
Project highlights, below:
Ref.: VitD3 Injectables / Aug 2023
Parameter
Product
Territory
Dossier requirement
Manufacturing site
Business model
Vitamin D3 injectable
EAEU markets + opportunities to expand into other ex-USSR nations
CTD
Licensor's EU GMP certificate in possession
Description
1. in-licensing agreement + FDF/in-bulk
2. supply technology transfer
2. supply technology transfer
